Screener
Stoke Therapeutics, Inc. STOK Stock-Based Comp
Stock-Based Comp at other companies
Other financials
Where this comes from
Reported directly by Stoke Therapeutics, Inc. in its filing.
Tagged under the XBRL concept us-gaap:ShareBasedCompensation.
The source filing: Stoke Therapeutics, Inc.’s 10-Q, filed May 7, 2026.
- Filed
- May 7, 2026, 4:06 PM EDT
- Fiscal quarter
- Q1 FY2026
- Calendar quarter
- Q1 2026
- Accession
- 0001193125-26-211874
| Line item | Three Months Ended March 31, 2026 | Three Months Ended March 31, 2025 |
|---|---|---|
| Adjustments to reconcile net (loss) income to net cash provided by (used in) operating activities: | ||
| Depreciation | 439 | 477 |
| Amortization and accretion of marketable securities | (365) | (494) |
| Stock-based compensation expense | 8,753 | 6,753 |
| Reduction in the carrying amount of right of use assets | 608 | 599 |
| Changes in assets and liabilities: | ||
| Accounts receivable | 1,486 | (1,325) |
| Prepaid expenses and other current assets | (3,588) | (1,230) |
Item 1. Financial Statements.
FAQ
- What is Stoke Therapeutics, Inc.'s stock-based comp?
- Stoke Therapeutics, Inc. (STOK) reported stock-based comp of $8.75M in Q1 2026.
- How has Stoke Therapeutics, Inc.'s stock-based comp changed year-over-year?
- Stoke Therapeutics, Inc.'s stock-based comp increased by 29.6% year-over-year, from $6.75M to $8.75M.
- What is the long-term trend for Stoke Therapeutics, Inc.'s stock-based comp?
- Over 4 years (2021 to 2025), Stoke Therapeutics, Inc.'s stock-based comp has grown at a 18.3% compound annual growth rate (CAGR), from $16.45M to $32.24M.
- What does stock-based comp mean?
- Total non-cash stock-based compensation expense for equity awards (RSUs, options, ESPP), added back to net income in cash flow reconciliation.
Ask your AI about Stoke Therapeutics, Inc.'s stock-based comp.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude